In:
Chemistry – A European Journal, Wiley, Vol. 28, No. 8 ( 2022-02-07)
Abstract:
Access to the cyclic depsipeptide FR900359 (FR), a selective G q/11 protein inhibitor of high pharmacological interest and a potential lead molecule for targeted therapy of cancers with oncogenic GNAQ or GNA11 mutations (encoding G q and G 11 respectively), has been challenging ever since its initial discovery more than three decades ago. The recent discovery of Chromobacterium vaccinii as a cultivable FR producer enables the development of approaches leading to a high‐yielding, scalable and sustainable biotechnological process for production of FR, thereby removing this bottleneck. Here we characterize different promoters in exchange of the native promoter of the FR assembly line, resulting in an overexpression mutant with significantly increased production of FR. Thereby, the isolation and structure elucidation of novel FR analogs of low abundance is enabled. Further, we explore the antiproliferative activities of fifteen chromodepsins against uveal melanoma cell lines harboring G q/11 mutations and characterize the major metabolite of FR formed in plasma.
Type of Medium:
Online Resource
ISSN:
0947-6539
,
1521-3765
DOI:
10.1002/chem.202103888
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
1478547-X
Permalink